BenevolentAI has uniquely developed an AI-augmented, hypothesis-driven drug discovery platform that generates novel targets at scale. In this talk, Dave Michalovich, SVP Precision Medicine, will explore how BenevolentAI bridges the worlds of drug discovery science and technology to help guide technologists in their work to develop AI tools that meet hyper-specific scientific requirements. Through use cases he will then demonstrate how BenevolentAI applies these tools to empower target identification, precision medicine and molecular design, citing BenevolentAI's work in novel target discovery, drug repurposing and in collaboration with large pharma.
Dave is responsible for driving the Precision Medicine strategy at BenevolentAI, taking a patient-centric approach to understand disease endotypes, mechanisms and targets. Prior to joining BenevolentAI Dave was a Senior Scientific Director at GSK where he led discovery teams in the Adaptive Immunity Research Unit and Respiratory TA.
